|
Market Closed -
Nasdaq
04:00:00 01/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 522.81 USD | -0.74% |
|
+1.52% | +15.32% |
| 09-28 | UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating | MT |
| 09-23 | TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 133,505 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 16.07% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 127,963 | 123,926 | 120,926 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | 18.03% | -3.15% | -2.42% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 54.1x | 28.5x | 24.1x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 8.55x | 6.78x | 5.5x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | -1.5x | 0.3x | 1.3x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 10.1x | 9.18x | 8.12x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 9.66x | 8.52x | 7.36x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 33.1x | 20x | 17.6x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 26.6x | 20.6x | 17.4x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 70.9x | 26.5x | 23.9x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 1.41% | 3.77% | 4.18% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 9.731 | 18.46 | 21.86 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,248 | 14,551 | 16,439 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 3,864 | 6,205 | 6,860 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 4,802 | 6,007 | 6,942 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 2,535 | 4,836 | 5,698 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -5,542 | -9,579 | -12,580 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 526.73 | 526.73 | 526.73 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,461 | - | - |
| Announcement Date | 26/1/22 | 7/2/23 | 5/2/24 | 10/2/25 | 12/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 54.13x | 9.66x | 33.12x | -.--% | 134B | |
| 33.68x | 12.2x | 24.79x | 0.59% | 1,056B | |
| 29.76x | 6.61x | 18.5x | 2% | 645B | |
| 33.32x | 7.79x | 16.11x | 2.63% | 465B | |
| 108.6x | 6.05x | 25.67x | 2.29% | 368B | |
| 19.01x | 4.64x | 11.49x | 2.87% | 335B | |
| 20.51x | 5.32x | 13.17x | 3.01% | 275B | |
| 20.92x | 4.34x | 12.36x | 2.04% | 255B | |
| 26.76x | 6.95x | 12.37x | 2.38% | 229B | |
| -45.76x | 6.66x | 26x | 2.18% | 188B | |
| Average | 30.09x | 7.02x | 19.36x | 2% | 394.93B | |
| Weighted average by Cap. | 33.52x | 7.91x | 19.70x | 1.83% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
